Literature DB >> 1855353

Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations.

K Fattinger1, S Vozeh, A Olafsson, J Vlcek, M Wenk, F Follath.   

Abstract

Netilmicin pharmacokinetics were studied in neonates of 27 to 42 weeks' gestational age and 0.8 to 5.0 kg body weight in their first 2 weeks of life by the population pharmacokinetic approach. The data were best described by a two-compartment model. Clearance depends on body weight, gestational age, and postnatal age. Volume of distribution of the central and peripheral compartments was also related to body weight. Including these patient characteristics in the population pharmacokinetic regression model resulted in a marked reduction of the unexplained interindividual variability. This enabled us to derive dosage recommendations that result in peak and average concentrations within the desired range for 95% of the neonates with gestational age above 31 weeks, thus avoiding the need for individual drug-level monitoring in a well-defined large group of patients. Only for infants with gestational age less than 31 weeks who are less than 6 days old is individual dose adjustment based on serum concentration measurements required.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855353     DOI: 10.1038/clpt.1991.103

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

Authors:  D B White; C A Walawander; D Y Liu; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

2.  Individualising netilmicin dosing in neonates.

Authors:  Catherine M T Sherwin; Roland S Broadbent; Natalie J Medlicott; David M Reith
Journal:  Eur J Clin Pharmacol       Date:  2008-08-07       Impact factor: 2.953

Review 3.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

4.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

5.  Once daily dosing of netilmicin in neonatal and pediatric intensive care.

Authors:  B P Wagner; J Pfenninger
Journal:  Intensive Care Med       Date:  1994-05       Impact factor: 17.440

6.  Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.

Authors:  J M Tréluyer; Y Merlé; S Tonnelier; E Rey; G Pons
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 7.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Population pharmacokinetics of gentamicin in South African newborns.

Authors:  J H Botha; M J du Preez; M Adhikari
Journal:  Eur J Clin Pharmacol       Date:  2003-10-18       Impact factor: 2.953

Review 9.  Time course of trough serum gentamicin concentrations in preterm and term neonates.

Authors:  M A de Cos; J Gómez-Ullate; F Gómez; J A Armijo
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

10.  Population pharmacokinetics of netilmicin in short-term prophylactic treatment.

Authors:  Nerea Jauregizar; Jeff A Wald; Ander Astobieta; Jose M Rodriguez Sasiain; John C Lukas; Rosario Calvo
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.